Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. [electronic resource]
Producer: 20130919Description: 844-54 p. digitalISSN:- 1365-2133
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Cardiovascular Diseases -- chemically induced
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Dermatologic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Infections -- chemically induced
- Male
- Middle Aged
- Neoplasms -- chemically induced
- Psoriasis -- drug therapy
- Randomized Controlled Trials as Topic
- Ustekinumab
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.